Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HUTCHMED (China) Limited (0013.HK)
Hong Kong, HK
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Fruquintinib targets CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a broad spectrum of gastrointestinal and solid tumors. Another prominent compound, Surufatinib, is indicated for various neuroendocrine tumors (NETs) including pancreatic and non-pancreatic types, alongside biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and other solid tumors. Further pipeline assets feature HMPL-523, a spleen tyrosine kinase (Syk) inhibitor for treating hematological cancers and certain chronic immune diseases; HMPL-689, an inhibitor specifically targeting the PI3Kd isoform; and Tazemetostat, an EZH2 inhibitor utilized in the treatment of specific epithelioid sarcoma and follicular lymphoma patients. The company's development efforts also encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase (BTK) inhibitor; HMPL-453, aimed at intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; HMPL-653, developed for metastatic solid tumors and tenosynovial giant cell tumors; and the inhibitors Epitinib (HMPL-813) and Theliatinib (HMPL-309). HUTCHMED has forged strategic collaboration agreements with a number of significant pharmaceutical entities, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company, originally known as Hutchison China MediTech Limited, officially changed its name to HUTCHMED (China) Limited in May 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.98% | -4.08% | -13.99% | -19.30% | -18.51% | -11.15% | -16.54% | -7.94% | -69.62% | -69.62% | -69.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 13 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-13.0% Q4'25: -16.5% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+1,103.7% ★ Q4'25: -102.0% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-30.4% Q4'25: +1.2% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-7.1% Q4'25: -13.2% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'25: +326.3% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.79× Q4'25: -1.72× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 12 EPS Ana. |
Dec 2027 21 Rev. Ana. 12 EPS Ana. |
Dec 2028 18 Rev. Ana. 7 EPS Ana. |
Dec 2029 10 Rev. Ana. 10 EPS Ana. |
Dec 2030 10 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
178.20M
est: 361.34M (-50.7%)
|
216.08M
est: 211.50M (+2.2%)
|
241.20M
est: 244.47M (-1.3%)
|
214.11M
est: 169.19M (+26.5%)
|
204.89M
est: 194.96M (+5.1%)
|
227.98M
est: 218.42M (+4.4%)
|
356.13M
est: 340.58M (+4.6%)
|
426.41M
est: 410.15M (+4.0%)
|
838.00M
est: 806.34M (+3.9%)
|
630.20M
est: 668.27M (-5.7%)
|
548.51M
est: 563.75M (-2.7%)
|
638.70M
595.62M – 752.17M
+13.3% YoY
|
740.01M
648.06M – 930.68M
+15.9% YoY
|
840.96M
758.70M – 1.03B
+13.6% YoY
|
1.05B
951.22M – 1.29B
+25.4% YoY
|
1.18B
1.07B – 1.45B
+12.4% YoY
|
| EBITDA |
-7.12M
est: -183.70M (+96.1%)
|
-43.38M
est: -107.52M (+59.7%)
|
-49.50M
est: -124.29M (+60.2%)
|
-82.06M
est: -86.02M (+4.6%)
|
-135.13M
est: -99.12M (-36.3%)
|
-182.89M
est: -111.04M (-64.7%)
|
-321.13M
est: -173.15M (-85.5%)
|
-401.11M
est: -208.51M (-92.4%)
|
67.27M
est: -409.93M (+116.4%)
|
14.11M
est: -238.82M (+105.9%)
|
-25.85M
est: -201.47M (+87.2%)
|
-228.25M
-268.80M – -212.86M
-13.3% YoY
|
-264.46M
-332.60M – -231.60M
-15.9% YoY
|
-300.53M
-366.78M – -271.14M
-13.6% YoY
|
-376.79M
-459.85M – -339.94M
-25.4% YoY
|
-423.38M
-516.70M – -381.97M
-12.4% YoY
|
| EBIT |
-9.14M
est: -190.67M (+95.2%)
|
-45.73M
est: -111.60M (+59.0%)
|
-52.08M
est: -129.00M (+59.6%)
|
-85.65M
est: -89.28M (+4.1%)
|
-140.08M
est: -102.88M (-36.2%)
|
-188.95M
est: -115.26M (-63.9%)
|
-328.32M
est: -179.72M (-82.7%)
|
-409.77M
est: -216.43M (-89.3%)
|
59.07M
est: -425.49M (+113.9%)
|
1.77M
est: -251.40M (+100.7%)
|
-39.16M
est: -212.08M (+81.5%)
|
-240.28M
-282.97M – -224.07M
-13.3% YoY
|
-278.39M
-350.12M – -243.80M
-15.9% YoY
|
-316.37M
-386.11M – -285.42M
-13.6% YoY
|
-396.64M
-484.08M – -357.85M
-25.4% YoY
|
-445.69M
-543.93M – -402.09M
-12.4% YoY
|
| Net Income |
7.99M
est: 19.97M (-60.0%)
|
11.70M
est: -220.38M (+105.3%)
|
-26.74M
est: -520.67M (+94.9%)
|
-74.81M
est: -1.47B (+94.9%)
|
-103.68M
est: -161.77M (+35.9%)
|
-125.73M
est: -174.13M (+27.8%)
|
-194.65M
est: -286.10M (+32.0%)
|
-360.84M
est: -362.56M (+0.5%)
|
100.78M
est: 9.05M (+1,014.1%)
|
37.73M
est: -4.94M (+864.1%)
|
456.91M
est: 469.39M (-2.7%)
|
53.28M
1.22M – 98.98M
-88.6% YoY
|
78.34M
40.60M – 133.69M
+47.0% YoY
|
104.39M
91.11M – 134.30M
+33.3% YoY
|
154.46M
134.82M – 198.72M
+48.0% YoY
|
204.24M
178.27M – 262.77M
+32.2% YoY
|
| SGA |
29.83M
est: 92.75M (-67.8%)
|
39.58M
est: 54.28M (-27.1%)
|
43.28M
est: 62.75M (-31.0%)
|
48.65M
est: 43.43M (+12.0%)
|
52.93M
est: 50.04M (+5.8%)
|
61.35M
est: 56.06M (+9.4%)
|
127.13M
est: 87.42M (+45.4%)
|
136.11M
est: 105.27M (+29.3%)
|
133.18M
est: 206.96M (-35.7%)
|
112.91M
est: 160.66M (-29.7%)
|
103.03M
est: 135.53M (-24.0%)
|
153.55M
143.20M – 180.83M
+13.3% YoY
|
177.91M
155.80M – 223.75M
+15.9% YoY
|
202.18M
182.40M – 246.75M
+13.6% YoY
|
253.48M
228.69M – 309.36M
+25.4% YoY
|
284.82M
256.96M – 347.61M
+12.4% YoY
|
| EPS |
-0.06
est: 0.02 (-379.6%)
|
0.02
est: -0.25 (+107.9%)
|
-0.04
est: -0.60 (+92.7%)
|
-0.11
est: -1.69 (+93.5%)
|
-0.22
est: -0.19 (-18.7%)
|
-0.18
est: -0.20 (+9.8%)
|
-0.25
est: -0.33 (+23.8%)
|
-0.43
est: -0.42 (-3.5%)
|
0.12
est: 0.01 (+1,057.5%)
|
0.04
est: -0.01 (+876.0%)
|
0.53
est: 0.54 (-1.4%)
|
0.06
0.00 – 0.11
-88.6% YoY
|
0.09
0.05 – 0.15
+47.0% YoY
|
0.12
0.10 – 0.15
+33.3% YoY
|
0.18
0.15 – 0.23
+48.0% YoY
|
0.23
0.20 – 0.30
+32.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.80% | 521.8K | 0.59% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.14% | 1.55M | 0.40% |
| 3 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.12% | 580.1K | 0.32% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.11% | 82.4K | 0.74% |
| 5 | iShares Ageing Population UCITS ETF AGED.L | 0.10% | 920.3K | 0.40% |
| 6 | iShares International Small-Cap Equity Factor ETF ISCF | 0.08% | 491.2K | 0.24% |
| 7 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.08% | 284.7K | 0.72% |
| 8 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.07% | 259.7K | 0.74% |
| 9 | Goldman Sachs Innovate Equity ETF GINN | 0.07% | 157.3K | 0.50% |
| 10 | Amundi UK Equity All Cap UCITS ETF Dist LCUK.L | 0.03% | 582.4K | 0.04% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Weiguo Su | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) | 14M | — |
| Chig Fung Cheng | Acting Chief Executive Officer, Chief Financial Officer & Executive Director | 9M | male |
| Kin Hung Lee | Senior Vice President of Corporate Management & Communications | — | male |
| Qingmei Wang | Executive Vice President of Business Development & Strategic Alliances | — | — |
| Selina Zhang | Senior Vice President of Global Human Resources | — | female |
| Thomas Fu | Senior Vice President of Global Quality | — | — |
| Xinhui Hu | Executive Vice President & Chief Technical Officer | — | — |
| Charles George Rupert Nixon | Group General Counsel | — | male |
| Yiling Cui | Executive Vice President & Head of Operations | — | female |
| David Ng | Head of Investor Relations & Capital Strategies | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0013.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
